Why would discussion of a substance used for decades in water treatment become so controversial that one of the world's largest video platforms specifically restricts its promotion as a medical treatment? In an interview with Redacted's Natalie Morris, critical-care physician Dr Pierre Kory argues that the story of chlorine dioxide raises much bigger questions about medical research, pharmaceutical economics, censorship and who ultimately decides which treatments are allowed to be investigated.
INR Report: Based on an interview by Natalie Morris of Redacted with Dr Pierre Kory.
Natalie Morris begins the interview with an unusual admission: the programme is not being presented on YouTube because of the subject it discusses.
The substance is chlorine dioxide, often associated with products marketed as "Miracle Mineral Solution", or MMS.
That restriction is not merely Morris's interpretation of YouTube's rules. YouTube's current Medical Misinformation Policy specifically lists MMS among substances it does not permit content to promote as a prevention or treatment because the platform considers it to present an inherent risk of severe bodily harm or death. YouTube does, however, provide potential exceptions for educational, documentary, scientific and public-interest discussion when sufficient context is provided.
That distinction is important.
The question raised by the interview is therefore not simply whether chlorine dioxide works as Kory claims. It is whether controversial medical propositions should be prohibited from public discussion before the underlying evidence has been openly examined.
What Is Chlorine Dioxide?
Kory describes chlorine dioxide as belonging to a class of substances known as oxidative agents.
In the interview, he explains oxidation in relatively simple chemical terms: an oxidising compound accepts electrons. He argues that when chlorine dioxide encounters microorganisms, this oxidation can damage cellular structures and thereby destroy certain microbes.
Chlorine dioxide does have established antimicrobial and disinfectant applications. It has been used in areas including water treatment, industrial sanitation and disinfection.
Where the controversy begins is with the next step.
Kory argues that its antimicrobial properties may have therapeutic applications inside the human body and contends that appropriately prepared chlorine dioxide can be administered orally at what he describes as therapeutic doses.
That is emphatically disputed by mainstream health regulators.
The US Food and Drug Administration has warned consumers against drinking products marketed as MMS and says it has received reports of severe vomiting, diarrhoea, life-threatening low blood pressure, acute liver failure and other serious adverse events following ingestion. The FDA has not approved MMS for treating COVID-19 or any other disease.
The competing positions could hardly be further apart.
Kory argues that chlorine dioxide has been unfairly characterised as simply "bleach". Regulators, meanwhile, warn that ingesting MMS products can be dangerous.
That disagreement lies at the centre of the interview.
Kory's Argument: Where Are the Trials?
Perhaps the most interesting aspect of Kory's argument is not that people should simply accept chlorine dioxide as a treatment.
He repeatedly calls for proper clinical investigation.
Kory recounts that when he first encountered claims surrounding chlorine dioxide, he himself was sceptical. He says the material he was reading appeared to describe something approaching a universal treatment, prompting him to search PubMed for supporting medical studies.
He says he initially found virtually nothing.
Rather than convincing him that the therapy worked, the absence of published research initially caused him to dismiss it.
Years later, according to Kory, conversations with physicians in South America caused him to reconsider the subject.
That experience led him to investigate what he now characterises as a history of ignored, suppressed or discredited research.
The critical question is whether that interpretation survives independent scrutiny.
The Bolivia Story
One of Kory's central examples concerns Bolivia during the COVID-19 pandemic.
He tells Morris that he became acquainted with a Bolivian surgeon who described the country's experience with chlorine dioxide during the pandemic.
According to Kory, legislators permitted its manufacture and distribution, the military became involved in production, and large numbers of people sought access to it. He says contemporary Bolivian television coverage sometimes presented both health ministry critics and clinicians who supported its use.
Kory argues that subsequent Western reporting characterised the episode overwhelmingly as dangerous desperation rather than examining whether health outcomes changed after chlorine dioxide became widely available.
He further claims that physicians involved were unable to obtain the data necessary to formally analyse the programme.
That presents an intriguing historical question, but correlation is not clinical proof. Changes in infection curves or hospital occupancy cannot by themselves establish that a particular treatment caused the improvement.
The stronger case would require patient-level data, appropriate controls, clearly defined treatment protocols and independent statistical analysis.
And that leads directly back to Kory's principal complaint: why, he asks, has that research not been undertaken?
The Extraordinary Red Cross Malaria Claim
The interview then moves into considerably more extraordinary territory.
Kory recounts what he describes as a chlorine dioxide trial involving 157 malaria patients in Uganda.
He says patients were confirmed as having malaria, received chlorine dioxide and were subsequently reported as recovering after one day of treatment.
More remarkably, Kory claims representatives associated with the local Red Cross operation participated and that a documentary film recorded the programme, its personnel and the reported results.
He then alleges that the International Red Cross subsequently distanced itself from the episode and disputed the legitimacy of the project.
A claimed 157-out-of-157 cure of malaria after one day's treatment would be an extraordinary medical result.
It therefore demands an equally extraordinary standard of evidence.
The existence of video, protocols or people describing what occurred would establish that an event took place; it would not by itself establish therapeutic efficacy. Patient records, diagnostic methodology, follow-up testing, treatment protocols and independently reviewable data would be necessary before such a result could responsibly be regarded as established.
But if the documentation Kory describes exists, the obvious journalistic question is why it has not received rigorous independent examination.
A Pattern of Suppression — Or Something Else?
Kory presents several historical stories which he believes demonstrate a recurring pattern.
These include allegations involving researchers whose work disappeared, studies which were retracted or disputed, and researchers who subsequently encountered legal or professional problems.
Morris also introduces historical claims involving inventor Nikola Tesla and German researcher Eugene Blass, suggesting their work may have represented predecessors to modern oxidative therapies.
Some of those claims are dramatic.
They should not be treated as established simply because they appear in the interview.
The transcript itself frequently moves between documented events, Kory's interpretation of events and historical allegations for which the underlying primary documentation would need to be independently authenticated.
For INR, that distinction matters.
A censorship claim becomes considerably stronger when the supposedly suppressed document can actually be produced.
The 1988 NASA Document
Kory points to what he says is a particularly interesting historical document: a 1988 NASA publication containing an article titled The Universal Antidote.
According to Kory, the article discussed chlorine dioxide and its potential applications, including veterinary and human uses.
What interests Kory is what happened afterwards.
He says he has been unable to find similarly favourable mainstream discussion of chlorine dioxide in subsequent decades and argues that public references increasingly became associated with warnings about "bleach".
Again, disappearance from mainstream discussion is not evidence that a treatment works.
But historical documents can establish something else: what scientists and institutions were willing to investigate at a particular point in time.
That makes the NASA material worth examining on its own merits.
Chlorite and the Pharmaceutical Question
Kory then introduces one of the interview's more scientifically interesting arguments.
He discusses chlorite, a chemical species related to chlorine dioxide, and claims pharmaceutical researchers have investigated intravenous chlorite formulations for neurological and other conditions.
He points specifically to research involving ALS and says randomised controlled trials have been undertaken.
His contention is that scientific papers examining chlorite rarely make the connection to chlorine dioxide explicit, despite the chemical relationship between them.
Kory argues this creates a striking contradiction: chlorine dioxide is publicly portrayed as dangerous and medically illegitimate while a related compound can simultaneously become the subject of conventional pharmaceutical development.
That does not establish that drinking chlorine dioxide is safe or therapeutically equivalent to receiving a controlled pharmaceutical formulation intravenously.
Dosage, purity, formulation, route of administration and pharmacology matter enormously.
But the underlying research question is legitimate: what exactly has been studied, what were the results, and how closely are those compounds pharmacologically related?
The Pharmaceutical Business Model
Kory believes the larger issue is economic.
Modern pharmaceutical development depends heavily upon intellectual property, patented compounds, regulatory approval and products capable of recovering enormous development costs.
An inexpensive substance which could be manufactured easily and used across multiple diseases would present a very different commercial proposition.
Kory takes the argument considerably further.
He tells Morris that a cheap, widely available and self-administered treatment capable of addressing numerous diseases would represent an enormous threat to the pharmaceutical industry.
That is Kory's thesis.
It should not automatically be confused with proof of coordinated suppression.
Pharmaceutical companies unquestionably have commercial incentives. But demonstrating that an industry has an economic motive to favour profitable medicines is different from demonstrating that regulators, journals, researchers and corporations collectively suppressed a particular effective therapy.
The latter requires evidence.
YouTube Has Made Its Decision
There is, however, one institution whose position is not ambiguous.
YouTube specifically identifies MMS within its medical misinformation rules.
The platform says it prohibits promotion of MMS as prevention or treatment because it considers the substance capable of causing serious physical injury or death.
That policy helps explain why Morris chose to distribute the interview elsewhere.
The significance extends beyond chlorine dioxide.
Private technology companies now exercise considerable influence over the boundaries of public medical debate. They must balance genuine risks from dangerous medical misinformation against the possibility that controversial or minority scientific opinions can sometimes be legitimate subjects for investigation.
YouTube itself recognises this tension by allowing possible educational, documentary, scientific and public-interest exceptions.
The question is where discussion ends and promotion begins.
The Regulatory Position Cannot Be Ignored
There is another side to this story which viewers should understand clearly.
The US FDA has repeatedly warned against drinking MMS or chlorine dioxide products marketed for disease treatment. The agency says it has received reports of serious adverse events and has not approved MMS for treating any disease.
Therefore, nothing in Kory's interview establishes that people should obtain chlorine dioxide and treat themselves.
Nor does the existence of chlorine dioxide in water-treatment systems establish that concentrated products are safe to ingest therapeutically. Exposure concentration and formulation are fundamental toxicological considerations.
That warning does not prevent examination of Kory's claims.
It makes rigorous examination more important.
The Question Science Should Be Able to Answer
Strip away the accusations, historical intrigue and pharmaceutical politics and a surprisingly straightforward question remains.
Does chlorine dioxide have clinically useful therapeutic properties at concentrations that are safe for human beings?
That is an empirical question.
It should be capable of being answered through chemistry, toxicology, pharmacokinetics, properly designed clinical trials and transparent publication of the results.
If the answer is no, high-quality research should demonstrate why.
If the answer is yes for particular applications, high-quality research should demonstrate that too.
And if potentially useful research has genuinely been ignored because there is little commercial incentive to investigate an inexpensive and unpatentable therapy, that would raise legitimate questions about how modern medical research priorities are determined.
Does This Affect New Zealand?
Absolutely.
Not because New Zealanders should begin experimenting with chlorine dioxide. They should not interpret this interview or this report as medical advice.
The wider issue is one of scientific freedom, public access to information and confidence in health institutions.
New Zealand increasingly obtains information through global digital platforms whose policies can determine which medical arguments millions of people encounter.
Some restrictions are intended to prevent genuine harm.
But democratic societies should also be cautious about allowing technology platforms, pharmaceutical companies, governments or any other institution to become unquestionable arbiters of scientific truth.
Science advances through evidence, replication, criticism and debate.
If Pierre Kory's claims are wrong, rigorous independent research should expose their weaknesses.
If some of them are right, rigorous independent research should establish that too.
Either way, simply preventing people from hearing the argument cannot substitute for answering it.
INR's position is straightforward: extraordinary medical claims require strong evidence — but controversial claims should still be capable of investigation.
The appropriate response to disputed science is better science.
Not blind acceptance.
And not blind censorship.
Important Medical Context
This report examines claims made during an interview and the public-interest issues surrounding scientific research and censorship. It does not endorse chlorine dioxide or MMS as a medical treatment and should not be interpreted as medical advice.
US regulators warn against ingesting MMS/chlorine dioxide products marketed as treatments and report serious adverse reactions. Anyone considering any medical treatment should obtain appropriate professional medical advice.
Source
Interview: Natalie Morris, Redacted, with Dr Pierre Kory.
YouTube Medical Misinformation Policy — current policy specifically identifies Miracle Mineral Solution (MMS) among substances whose promotion as treatment or prevention is prohibited.
US Food and Drug Administration — regulatory warnings concerning ingestion of MMS/chlorine dioxide products.
Independent reporting. Original context. Credited sources.